TrialAnnals of the rheumatic diseases2016

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

Munther Khamashta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.